Safety recommendation
It is recommended that NHSX continues its assessment of the ePRaSE [ePrescribing Risk and Safety Evaluation] pilot and considers making ePRaSE a mandatory annual reporting requirement for the assessment and assurance of electronic prescribing and medicines administration safety.
Response:
In response to the report’s recommendation on assessing the ePRaSE pilot, we have completed said pilot and have identified a number of accessibility challenges. We are now focused on learning from the initial pilot, so that we can initiate an extended Alpha phase pilot in May 2020 before making any final decision on the full adoption of the tool.